This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Email: (change)

Frequency:

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2023 Feb;151(2):579.

doi: 10.1016/j.jaci.2022.12.001.

Corrigendum

No authors listed

PMID: 36740328
DOI: 10.1016/j.jaci.2022.12.001

Free article

Published Erratum

Corrigendum

No authors listed. J Allergy Clin Immunol. 2023 Feb.

Free article

. 2023 Feb;151(2):579.

doi: 10.1016/j.jaci.2022.12.001.

PMID: 36740328
DOI: 10.1016/j.jaci.2022.12.001

No abstract available

PubMed Disclaimer

Erratum for

Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
Maurer M, Berger W, Giménez-Arnau A, Hayama K, Jain V, Reich A, Haemmerle S, Lheritier K, Walsh P, Xia S, Storim J. Maurer M, et al. J Allergy Clin Immunol. 2022 Dec;150(6):1498-1506.e2. doi: 10.1016/j.jaci.2022.08.027. Epub 2022 Sep 9. J Allergy Clin Immunol. 2022. PMID: 36096203 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum

Corrigendum

Erratum for

Publication types

LinkOut - more resources

Full Text Sources